Bausch + Lomb Corporation (BLCO) exhibits 41.0% gross margins and 0.8% return on invested capital within Health Care (Ophthalmic Goods), balanced against a 29.1x enterprise multiple and 7.1% implied options volatility.
Sustained 41.0% gross profitability converts into 2.2% operating margin and 0.8% ROIC, outpacing sector cost of capital.
ROIC: 0.8% // GM: 41.0%YoY revenue trajectory of +6.5% paired with -0.90% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +6.5% // FCF YLD: -0.90%Altman Z-Score of 0.97 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 0.97 // F-SCORE: 6/9Trading at 24.0x trailing P/E (23.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 29.1xOptions market prices a ±7.1% implied move with a 0.83 put/call ratio around $20.00 max pain.
IMPL MOVE: ±7.1% // P/C: 0.83Elevated industry capital intensity and customer concentration in Ophthalmic Goods require continuous execution to defend -7.1% net margins.
NET MARGIN: -7.1% // D/E: 0.78x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for BLCO & activate live FRED threshold breach alerts.